aluates Reports

$ 0.0

Automative

Global Chemotherapy Induced Neutropenia（CIN）Drug Market Research Report 2025

Published Date: March 2025

Report Code: QYRE-Auto-10K19217

BUY CHAPTERS

Global Chemotherapy Induced Neutropenia（CIN）Drug Market Research Report 2025

Code: QYRE-Auto-10K19217

Report

March 2025

Pages:92

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Sandoz Inc

Apotex

Pfizer Inc

Teva Pharmaceuticals

Amgen Inc

CSPC Pharmaceutical Group

Qilu Pharmaceutical

Shandong New Era Pharmaceutical

Jiuyuan Gene

Yifan Pharmaceutical

Xiamen Amoytop Biotech

Beijing SL Pharmaceutical

Assertio Holdings

B. Braun Holding GmbH

Chongqing Fujin Biological Medicine

Evive Biopharma

Chemotherapy Induced Neutropenia（CIN）Drug Market Size

The global market for Chemotherapy Induced Neutropenia（CIN）Drug was valued at US$ 606 million in the year 2024 and is projected to reach a revised size of US$ 781 million by 2031, growing at a CAGR of 3.7% during the forecast period.

Chemotherapy Induced Neutropenia（CIN）Drug Market

Chemotherapy-induced neutropenia (CIN) drugs refer to drugs used to prevent or treat chemotherapy-induced neutropenia. These drugs are mainly recombinant Human granulocyte colony-stimulating factor (rhG-CSF) and its pegylated form, which increase the number of neutrophils in the blood by stimulating the production of neutrophils in the bone marrow, thereby reducing the risk of infection in patients. These drugs play an important role in the supportive treatment of chemotherapy patients.

North American market for Chemotherapy Induced Neutropenia（CIN）Drug is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Chemotherapy Induced Neutropenia（CIN）Drug is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global market for Chemotherapy Induced Neutropenia（CIN）Drug in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Chemotherapy Induced Neutropenia（CIN）Drug include Sandoz, Apotex, Pfizer, Teva Pharmaceuticals, Amgen, Assertio Holdings, B. Braun Holding GmbH, CSPC Pharmaceutical Group, Qilu Pharmaceutical, Shandong New Era Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Chemotherapy Induced Neutropenia（CIN）Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotherapy Induced Neutropenia（CIN）Drug.

The Chemotherapy Induced Neutropenia（CIN）Drug market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chemotherapy Induced Neutropenia（CIN）Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Chemotherapy Induced Neutropenia（CIN）Drug companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Chemotherapy Induced Neutropenia（CIN）Drug Market Report

Report Metric	Details
Report Name	Chemotherapy Induced Neutropenia（CIN）Drug Market
Accounted market size in year	US$ 606 million
Forecasted market size in 2031	US$ 781 million
CAGR	3.7%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Injection Oral Preparation
Segment by Application	Hospital Clinic Others
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Sandoz, Apotex, Pfizer, Teva Pharmaceuticals, Amgen, Assertio Holdings, B. Braun Holding GmbH, CSPC Pharmaceutical Group, Qilu Pharmaceutical, Shandong New Era Pharmaceutical, Chongqing Fujin Biological Medicine, Jiuyuan Gene, Evive Biopharma, Yifan Pharmaceutical, Xiamen Amoytop Biotech, Beijing SL Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Chemotherapy Induced Neutropenia（CIN）Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Chemotherapy Induced Neutropenia（CIN）Drug Market growing?

Ans: The Chemotherapy Induced Neutropenia（CIN）Drug Market witnessing a CAGR of 3.7% during the forecast period 2025-2031.

What is the Chemotherapy Induced Neutropenia（CIN）Drug Market size in 2031?

Ans: The Chemotherapy Induced Neutropenia（CIN）Drug Market size in 2031 will be US$ 781 million.

Who are the main players in the Chemotherapy Induced Neutropenia（CIN）Drug Market report?

Ans: The main players in the Chemotherapy Induced Neutropenia（CIN）Drug Market are Sandoz, Apotex, Pfizer, Teva Pharmaceuticals, Amgen, Assertio Holdings, B. Braun Holding GmbH, CSPC Pharmaceutical Group, Qilu Pharmaceutical, Shandong New Era Pharmaceutical, Chongqing Fujin Biological Medicine, Jiuyuan Gene, Evive Biopharma, Yifan Pharmaceutical, Xiamen Amoytop Biotech, Beijing SL Pharmaceutical

What are the Application segmentation covered in the Chemotherapy Induced Neutropenia（CIN）Drug Market report?

Ans: The Applications covered in the Chemotherapy Induced Neutropenia（CIN）Drug Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Chemotherapy Induced Neutropenia（CIN）Drug Market report?

Ans: The Types covered in the Chemotherapy Induced Neutropenia（CIN）Drug Market report are Injection, Oral Preparation

Recommended Reports

Cancer Supportive Drugs

Hematological Diseases

Oncology Therapeutics

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Chemotherapy Induced Neutropenia（CIN）Drug Market Size Growth Rate by Type: 2020 VS 2024 VS 2031

1.2.2 Injection

1.2.3 Oral Preparation

1.3 Market by Application

1.3.1 Global Chemotherapy Induced Neutropenia（CIN）Drug Market Growth by Application: 2020 VS 2024 VS 2031

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Chemotherapy Induced Neutropenia（CIN）Drug Market Perspective (2020-2031)

2.2 Global Chemotherapy Induced Neutropenia（CIN）Drug Growth Trends by Region

2.2.1 Global Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Region: 2020 VS 2024 VS 2031

2.2.2 Chemotherapy Induced Neutropenia（CIN）Drug Historic Market Size by Region (2020-2025)

2.2.3 Chemotherapy Induced Neutropenia（CIN）Drug Forecasted Market Size by Region (2026-2031)

2.3 Chemotherapy Induced Neutropenia（CIN）Drug Market Dynamics

2.3.1 Chemotherapy Induced Neutropenia（CIN）Drug Industry Trends

2.3.2 Chemotherapy Induced Neutropenia（CIN）Drug Market Drivers

2.3.3 Chemotherapy Induced Neutropenia（CIN）Drug Market Challenges

2.3.4 Chemotherapy Induced Neutropenia（CIN）Drug Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Chemotherapy Induced Neutropenia（CIN）Drug Players by Revenue

3.1.1 Global Top Chemotherapy Induced Neutropenia（CIN）Drug Players by Revenue (2020-2025)

3.1.2 Global Chemotherapy Induced Neutropenia（CIN）Drug Revenue Market Share by Players (2020-2025)

3.2 Global Top Chemotherapy Induced Neutropenia（CIN）Drug Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Chemotherapy Induced Neutropenia（CIN）Drug Revenue

3.4 Global Chemotherapy Induced Neutropenia（CIN）Drug Market Concentration Ratio

3.4.1 Global Chemotherapy Induced Neutropenia（CIN）Drug Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Chemotherapy Induced Neutropenia（CIN）Drug Revenue in 2024

3.5 Global Key Players of Chemotherapy Induced Neutropenia（CIN）Drug Head office and Area Served

3.6 Global Key Players of Chemotherapy Induced Neutropenia（CIN）Drug, Product and Application

3.7 Global Key Players of Chemotherapy Induced Neutropenia（CIN）Drug, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Chemotherapy Induced Neutropenia（CIN）Drug Breakdown Data by Type

4.1 Global Chemotherapy Induced Neutropenia（CIN）Drug Historic Market Size by Type (2020-2025)

4.2 Global Chemotherapy Induced Neutropenia（CIN）Drug Forecasted Market Size by Type (2026-2031)

5 Chemotherapy Induced Neutropenia（CIN）Drug Breakdown Data by Application

5.1 Global Chemotherapy Induced Neutropenia（CIN）Drug Historic Market Size by Application (2020-2025)

5.2 Global Chemotherapy Induced Neutropenia（CIN）Drug Forecasted Market Size by Application (2026-2031)

6 North America

6.1 North America Chemotherapy Induced Neutropenia（CIN）Drug Market Size (2020-2031)

6.2 North America Chemotherapy Induced Neutropenia（CIN）Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031

6.3 North America Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Country (2020-2025)

6.4 North America Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Country (2026-2031)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Chemotherapy Induced Neutropenia（CIN）Drug Market Size (2020-2031)

7.2 Europe Chemotherapy Induced Neutropenia（CIN）Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031

7.3 Europe Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Country (2020-2025)

7.4 Europe Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Country (2026-2031)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Chemotherapy Induced Neutropenia（CIN）Drug Market Size (2020-2031)

8.2 Asia-Pacific Chemotherapy Induced Neutropenia（CIN）Drug Market Growth Rate by Region: 2020 VS 2024 VS 2031

8.3 Asia-Pacific Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Region (2020-2025)

8.4 Asia-Pacific Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Region (2026-2031)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Chemotherapy Induced Neutropenia（CIN）Drug Market Size (2020-2031)

9.2 Latin America Chemotherapy Induced Neutropenia（CIN）Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031

9.3 Latin America Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Country (2020-2025)

9.4 Latin America Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Country (2026-2031)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Chemotherapy Induced Neutropenia（CIN）Drug Market Size (2020-2031)

10.2 Middle East & Africa Chemotherapy Induced Neutropenia（CIN）Drug Market Growth Rate by Country: 2020 VS 2024 VS 2031

10.3 Middle East & Africa Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Country (2020-2025)

10.4 Middle East & Africa Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Country (2026-2031)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Sandoz

11.1.1 Sandoz Company Details

11.1.2 Sandoz Business Overview

11.1.3 Sandoz Chemotherapy Induced Neutropenia（CIN）Drug Introduction

11.1.4 Sandoz Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

11.1.5 Sandoz Recent Development

11.2 Apotex

11.2.1 Apotex Company Details

11.2.2 Apotex Business Overview

11.2.3 Apotex Chemotherapy Induced Neutropenia（CIN）Drug Introduction

11.2.4 Apotex Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

11.2.5 Apotex Recent Development

11.3 Pfizer

11.3.1 Pfizer Company Details

11.3.2 Pfizer Business Overview

11.3.3 Pfizer Chemotherapy Induced Neutropenia（CIN）Drug Introduction

11.3.4 Pfizer Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

11.3.5 Pfizer Recent Development

11.4 Teva Pharmaceuticals

11.4.1 Teva Pharmaceuticals Company Details

11.4.2 Teva Pharmaceuticals Business Overview

11.4.3 Teva Pharmaceuticals Chemotherapy Induced Neutropenia（CIN）Drug Introduction

11.4.4 Teva Pharmaceuticals Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

11.4.5 Teva Pharmaceuticals Recent Development

11.5 Amgen

11.5.1 Amgen Company Details

11.5.2 Amgen Business Overview

11.5.3 Amgen Chemotherapy Induced Neutropenia（CIN）Drug Introduction

11.5.4 Amgen Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

11.5.5 Amgen Recent Development

11.6 Assertio Holdings

11.6.1 Assertio Holdings Company Details

11.6.2 Assertio Holdings Business Overview

11.6.3 Assertio Holdings Chemotherapy Induced Neutropenia（CIN）Drug Introduction

11.6.4 Assertio Holdings Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

11.6.5 Assertio Holdings Recent Development

11.7 B. Braun Holding GmbH

11.7.1 B. Braun Holding GmbH Company Details

11.7.2 B. Braun Holding GmbH Business Overview

11.7.3 B. Braun Holding GmbH Chemotherapy Induced Neutropenia（CIN）Drug Introduction

11.7.4 B. Braun Holding GmbH Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

11.7.5 B. Braun Holding GmbH Recent Development

11.8 CSPC Pharmaceutical Group

11.8.1 CSPC Pharmaceutical Group Company Details

11.8.2 CSPC Pharmaceutical Group Business Overview

11.8.3 CSPC Pharmaceutical Group Chemotherapy Induced Neutropenia（CIN）Drug Introduction

11.8.4 CSPC Pharmaceutical Group Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

11.8.5 CSPC Pharmaceutical Group Recent Development

11.9 Qilu Pharmaceutical

11.9.1 Qilu Pharmaceutical Company Details

11.9.2 Qilu Pharmaceutical Business Overview

11.9.3 Qilu Pharmaceutical Chemotherapy Induced Neutropenia（CIN）Drug Introduction

11.9.4 Qilu Pharmaceutical Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

11.9.5 Qilu Pharmaceutical Recent Development

11.10 Shandong New Era Pharmaceutical

11.10.1 Shandong New Era Pharmaceutical Company Details

11.10.2 Shandong New Era Pharmaceutical Business Overview

11.10.3 Shandong New Era Pharmaceutical Chemotherapy Induced Neutropenia（CIN）Drug Introduction

11.10.4 Shandong New Era Pharmaceutical Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

11.10.5 Shandong New Era Pharmaceutical Recent Development

11.11 Chongqing Fujin Biological Medicine

11.11.1 Chongqing Fujin Biological Medicine Company Details

11.11.2 Chongqing Fujin Biological Medicine Business Overview

11.11.3 Chongqing Fujin Biological Medicine Chemotherapy Induced Neutropenia（CIN）Drug Introduction

11.11.4 Chongqing Fujin Biological Medicine Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

11.11.5 Chongqing Fujin Biological Medicine Recent Development

11.12 Jiuyuan Gene

11.12.1 Jiuyuan Gene Company Details

11.12.2 Jiuyuan Gene Business Overview

11.12.3 Jiuyuan Gene Chemotherapy Induced Neutropenia（CIN）Drug Introduction

11.12.4 Jiuyuan Gene Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

11.12.5 Jiuyuan Gene Recent Development

11.13 Evive Biopharma

11.13.1 Evive Biopharma Company Details

11.13.2 Evive Biopharma Business Overview

11.13.3 Evive Biopharma Chemotherapy Induced Neutropenia（CIN）Drug Introduction

11.13.4 Evive Biopharma Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

11.13.5 Evive Biopharma Recent Development

11.14 Yifan Pharmaceutical

11.14.1 Yifan Pharmaceutical Company Details

11.14.2 Yifan Pharmaceutical Business Overview

11.14.3 Yifan Pharmaceutical Chemotherapy Induced Neutropenia（CIN）Drug Introduction

11.14.4 Yifan Pharmaceutical Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

11.14.5 Yifan Pharmaceutical Recent Development

11.15 Xiamen Amoytop Biotech

11.15.1 Xiamen Amoytop Biotech Company Details

11.15.2 Xiamen Amoytop Biotech Business Overview

11.15.3 Xiamen Amoytop Biotech Chemotherapy Induced Neutropenia（CIN）Drug Introduction

11.15.4 Xiamen Amoytop Biotech Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

11.15.5 Xiamen Amoytop Biotech Recent Development

11.16 Beijing SL Pharmaceutical

11.16.1 Beijing SL Pharmaceutical Company Details

11.16.2 Beijing SL Pharmaceutical Business Overview

11.16.3 Beijing SL Pharmaceutical Chemotherapy Induced Neutropenia（CIN）Drug Introduction

11.16.4 Beijing SL Pharmaceutical Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

11.16.5 Beijing SL Pharmaceutical Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Sandoz Inc

Apotex

Pfizer Inc

Teva Pharmaceuticals

Amgen Inc

CSPC Pharmaceutical Group

Qilu Pharmaceutical

Shandong New Era Pharmaceutical

Jiuyuan Gene

Yifan Pharmaceutical

Xiamen Amoytop Biotech

Beijing SL Pharmaceutical

Assertio Holdings

B. Braun Holding GmbH

Chongqing Fujin Biological Medicine

Evive Biopharma

List of Tables

Table 1. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Key Players of Injection

Table 3. Key Players of Oral Preparation

Table 4. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 5. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 6. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Region (2020-2025) & (US$ Million)

Table 7. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Share by Region (2020-2025)

Table 8. Global Chemotherapy Induced Neutropenia（CIN）Drug Forecasted Market Size by Region (2026-2031) & (US$ Million)

Table 9. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Share by Region (2026-2031)

Table 10. Chemotherapy Induced Neutropenia（CIN）Drug Market Trends

Table 11. Chemotherapy Induced Neutropenia（CIN）Drug Market Drivers

Table 12. Chemotherapy Induced Neutropenia（CIN）Drug Market Challenges

Table 13. Chemotherapy Induced Neutropenia（CIN）Drug Market Restraints

Table 14. Global Chemotherapy Induced Neutropenia（CIN）Drug Revenue by Players (2020-2025) & (US$ Million)

Table 15. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Share by Players (2020-2025)

Table 16. Global Top Chemotherapy Induced Neutropenia（CIN）Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy Induced Neutropenia（CIN）Drug as of 2024)

Table 17. Ranking of Global Top Chemotherapy Induced Neutropenia（CIN）Drug Companies by Revenue (US$ Million) in 2024

Table 18. Global 5 Largest Players Market Share by Chemotherapy Induced Neutropenia（CIN）Drug Revenue (CR5 and HHI) & (2020-2025)

Table 19. Global Key Players of Chemotherapy Induced Neutropenia（CIN）Drug, Headquarters and Area Served

Table 20. Global Key Players of Chemotherapy Induced Neutropenia（CIN）Drug, Product and Application

Table 21. Global Key Players of Chemotherapy Induced Neutropenia（CIN）Drug, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Type (2020-2025) & (US$ Million)

Table 24. Global Chemotherapy Induced Neutropenia（CIN）Drug Revenue Market Share by Type (2020-2025)

Table 25. Global Chemotherapy Induced Neutropenia（CIN）Drug Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 26. Global Chemotherapy Induced Neutropenia（CIN）Drug Revenue Market Share by Type (2026-2031)

Table 27. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Application (2020-2025) & (US$ Million)

Table 28. Global Chemotherapy Induced Neutropenia（CIN）Drug Revenue Market Share by Application (2020-2025)

Table 29. Global Chemotherapy Induced Neutropenia（CIN）Drug Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 30. Global Chemotherapy Induced Neutropenia（CIN）Drug Revenue Market Share by Application (2026-2031)

Table 31. North America Chemotherapy Induced Neutropenia（CIN）Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 32. North America Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Country (2020-2025) & (US$ Million)

Table 33. North America Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Country (2026-2031) & (US$ Million)

Table 34. Europe Chemotherapy Induced Neutropenia（CIN）Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 35. Europe Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Country (2020-2025) & (US$ Million)

Table 36. Europe Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Country (2026-2031) & (US$ Million)

Table 37. Asia-Pacific Chemotherapy Induced Neutropenia（CIN）Drug Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031

Table 38. Asia-Pacific Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Region (2020-2025) & (US$ Million)

Table 39. Asia-Pacific Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Region (2026-2031) & (US$ Million)

Table 40. Latin America Chemotherapy Induced Neutropenia（CIN）Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 41. Latin America Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Country (2020-2025) & (US$ Million)

Table 42. Latin America Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Country (2026-2031) & (US$ Million)

Table 43. Middle East & Africa Chemotherapy Induced Neutropenia（CIN）Drug Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031

Table 44. Middle East & Africa Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Country (2020-2025) & (US$ Million)

Table 45. Middle East & Africa Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Country (2026-2031) & (US$ Million)

Table 46. Sandoz Company Details

Table 47. Sandoz Business Overview

Table 48. Sandoz Chemotherapy Induced Neutropenia（CIN）Drug Product

Table 49. Sandoz Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025) & (US$ Million)

Table 50. Sandoz Recent Development

Table 51. Apotex Company Details

Table 52. Apotex Business Overview

Table 53. Apotex Chemotherapy Induced Neutropenia（CIN）Drug Product

Table 54. Apotex Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025) & (US$ Million)

Table 55. Apotex Recent Development

Table 56. Pfizer Company Details

Table 57. Pfizer Business Overview

Table 58. Pfizer Chemotherapy Induced Neutropenia（CIN）Drug Product

Table 59. Pfizer Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025) & (US$ Million)

Table 60. Pfizer Recent Development

Table 61. Teva Pharmaceuticals Company Details

Table 62. Teva Pharmaceuticals Business Overview

Table 63. Teva Pharmaceuticals Chemotherapy Induced Neutropenia（CIN）Drug Product

Table 64. Teva Pharmaceuticals Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025) & (US$ Million)

Table 65. Teva Pharmaceuticals Recent Development

Table 66. Amgen Company Details

Table 67. Amgen Business Overview

Table 68. Amgen Chemotherapy Induced Neutropenia（CIN）Drug Product

Table 69. Amgen Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025) & (US$ Million)

Table 70. Amgen Recent Development

Table 71. Assertio Holdings Company Details

Table 72. Assertio Holdings Business Overview

Table 73. Assertio Holdings Chemotherapy Induced Neutropenia（CIN）Drug Product

Table 74. Assertio Holdings Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025) & (US$ Million)

Table 75. Assertio Holdings Recent Development

Table 76. B. Braun Holding GmbH Company Details

Table 77. B. Braun Holding GmbH Business Overview

Table 78. B. Braun Holding GmbH Chemotherapy Induced Neutropenia（CIN）Drug Product

Table 79. B. Braun Holding GmbH Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025) & (US$ Million)

Table 80. B. Braun Holding GmbH Recent Development

Table 81. CSPC Pharmaceutical Group Company Details

Table 82. CSPC Pharmaceutical Group Business Overview

Table 83. CSPC Pharmaceutical Group Chemotherapy Induced Neutropenia（CIN）Drug Product

Table 84. CSPC Pharmaceutical Group Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025) & (US$ Million)

Table 85. CSPC Pharmaceutical Group Recent Development

Table 86. Qilu Pharmaceutical Company Details

Table 87. Qilu Pharmaceutical Business Overview

Table 88. Qilu Pharmaceutical Chemotherapy Induced Neutropenia（CIN）Drug Product

Table 89. Qilu Pharmaceutical Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025) & (US$ Million)

Table 90. Qilu Pharmaceutical Recent Development

Table 91. Shandong New Era Pharmaceutical Company Details

Table 92. Shandong New Era Pharmaceutical Business Overview

Table 93. Shandong New Era Pharmaceutical Chemotherapy Induced Neutropenia（CIN）Drug Product

Table 94. Shandong New Era Pharmaceutical Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025) & (US$ Million)

Table 95. Shandong New Era Pharmaceutical Recent Development

Table 96. Chongqing Fujin Biological Medicine Company Details

Table 97. Chongqing Fujin Biological Medicine Business Overview

Table 98. Chongqing Fujin Biological Medicine Chemotherapy Induced Neutropenia（CIN）Drug Product

Table 99. Chongqing Fujin Biological Medicine Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025) & (US$ Million)

Table 100. Chongqing Fujin Biological Medicine Recent Development

Table 101. Jiuyuan Gene Company Details

Table 102. Jiuyuan Gene Business Overview

Table 103. Jiuyuan Gene Chemotherapy Induced Neutropenia（CIN）Drug Product

Table 104. Jiuyuan Gene Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025) & (US$ Million)

Table 105. Jiuyuan Gene Recent Development

Table 106. Evive Biopharma Company Details

Table 107. Evive Biopharma Business Overview

Table 108. Evive Biopharma Chemotherapy Induced Neutropenia（CIN）Drug Product

Table 109. Evive Biopharma Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025) & (US$ Million)

Table 110. Evive Biopharma Recent Development

Table 111. Yifan Pharmaceutical Company Details

Table 112. Yifan Pharmaceutical Business Overview

Table 113. Yifan Pharmaceutical Chemotherapy Induced Neutropenia（CIN）Drug Product

Table 114. Yifan Pharmaceutical Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025) & (US$ Million)

Table 115. Yifan Pharmaceutical Recent Development

Table 116. Xiamen Amoytop Biotech Company Details

Table 117. Xiamen Amoytop Biotech Business Overview

Table 118. Xiamen Amoytop Biotech Chemotherapy Induced Neutropenia（CIN）Drug Product

Table 119. Xiamen Amoytop Biotech Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025) & (US$ Million)

Table 120. Xiamen Amoytop Biotech Recent Development

Table 121. Beijing SL Pharmaceutical Company Details

Table 122. Beijing SL Pharmaceutical Business Overview

Table 123. Beijing SL Pharmaceutical Chemotherapy Induced Neutropenia（CIN）Drug Product

Table 124. Beijing SL Pharmaceutical Revenue in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025) & (US$ Million)

Table 125. Beijing SL Pharmaceutical Recent Development

Table 126. Research Programs/Design for This Report

Table 127. Key Data Information from Secondary Sources

Table 128. Key Data Information from Primary Sources

Table 129. Authors List of This Report

List of Figures

Figure 1. Chemotherapy Induced Neutropenia（CIN）Drug Picture

Figure 2. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Size Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Share by Type: 2024 VS 2031

Figure 4. Injection Features

Figure 5. Oral Preparation Features

Figure 6. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Size by Application (2020-2031) & (US$ Million)

Figure 7. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Share by Application: 2024 VS 2031

Figure 8. Hospital Case Studies

Figure 9. Clinic Case Studies

Figure 10. Others Case Studies

Figure 11. Chemotherapy Induced Neutropenia（CIN）Drug Report Years Considered

Figure 12. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Share by Region: 2024 VS 2031

Figure 15. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Share by Players in 2024

Figure 16. Global Chemotherapy Induced Neutropenia（CIN）Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 17. The Top 10 and 5 Players Market Share by Chemotherapy Induced Neutropenia（CIN）Drug Revenue in 2024

Figure 18. North America Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 19. North America Chemotherapy Induced Neutropenia（CIN）Drug Market Share by Country (2020-2031)

Figure 20. United States Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 21. Canada Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 22. Europe Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 23. Europe Chemotherapy Induced Neutropenia（CIN）Drug Market Share by Country (2020-2031)

Figure 24. Germany Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 25. France Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 26. U.K. Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 27. Italy Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 28. Russia Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 29. Nordic Countries Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 30. Asia-Pacific Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 31. Asia-Pacific Chemotherapy Induced Neutropenia（CIN）Drug Market Share by Region (2020-2031)

Figure 32. China Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 33. Japan Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 34. South Korea Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 35. Southeast Asia Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 36. India Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 37. Australia Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 38. Latin America Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 39. Latin America Chemotherapy Induced Neutropenia（CIN）Drug Market Share by Country (2020-2031)

Figure 40. Mexico Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 41. Brazil Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 42. Middle East & Africa Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 43. Middle East & Africa Chemotherapy Induced Neutropenia（CIN）Drug Market Share by Country (2020-2031)

Figure 44. Turkey Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 45. Saudi Arabia Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 46. UAE Chemotherapy Induced Neutropenia（CIN）Drug Market Size YoY Growth (2020-2031) & (US$ Million)

Figure 47. Sandoz Revenue Growth Rate in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

Figure 48. Apotex Revenue Growth Rate in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

Figure 49. Pfizer Revenue Growth Rate in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

Figure 50. Teva Pharmaceuticals Revenue Growth Rate in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

Figure 51. Amgen Revenue Growth Rate in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

Figure 52. Assertio Holdings Revenue Growth Rate in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

Figure 53. B. Braun Holding GmbH Revenue Growth Rate in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

Figure 54. CSPC Pharmaceutical Group Revenue Growth Rate in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

Figure 55. Qilu Pharmaceutical Revenue Growth Rate in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

Figure 56. Shandong New Era Pharmaceutical Revenue Growth Rate in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

Figure 57. Chongqing Fujin Biological Medicine Revenue Growth Rate in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

Figure 58. Jiuyuan Gene Revenue Growth Rate in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

Figure 59. Evive Biopharma Revenue Growth Rate in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

Figure 60. Yifan Pharmaceutical Revenue Growth Rate in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

Figure 61. Xiamen Amoytop Biotech Revenue Growth Rate in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

Figure 62. Beijing SL Pharmaceutical Revenue Growth Rate in Chemotherapy Induced Neutropenia（CIN）Drug Business (2020-2025)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Pegfilgrastim Market Insights Forecast to 2030

Global Recombinant Human Granulocyte Colony Stimulating Factor Injection rhG CSF Market Research Report 2025

Global Recombinant Human Granulocyte Colony Stimulating Market Insights Forecast to 2030

Chemotherapy induced Nausea and Vomiting Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Chemotheraphy Induced Nausea and Vomitting CINV Drugs Market Insights Forecast to 2030

Global Treatment of Chemotherapy Induced Nausea in Cancer Patients Market Research Report 2025

Global Chemotherapy Induced Nausea and Vomiting CINV Drugs Market Insights Forecast to 2030

Global Chemotherapy induced Nausea and Vomiting Treatment Market Research Report 2025

Global Chemotherapy Induced Myelosuppression Treatments Market Research Report 2024

Global Chemotherapy Induced Thrombocytopenia Drugs Market Research Report 2024

Global Chemotherapy Induced Anemia Drug Market Research Report 2024

Cancer Therapeutics and Supportive Care Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Insights Forecast to 2030

Global Filgrastim Injection Market Research Report 2024

Global Chemotherapy Induced Oral Mucositis Treatment Market Research Report 2024

Granulocyte Colony Stimulating Factor G CSF Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Targeted Chemotherapy Drugs Market Research Report 2024

Global Recombinant Human GM CSF for Injection Market Research Report 2024

Pegfilgrastim Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions